Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort (2024)
https://pubmed.ncbi.nlm.nih.gov/37995469/

Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature (2023)
https://pubmed.ncbi.nlm.nih.gov/38071514/

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study (2023)
https://pubmed.ncbi.nlm.nih.gov/37322274/

Quantitative proteomic screening uncovers candidate diagnostic and monitoring serum biomarkers of ankylosing spondylitis (2023)
https://pubmed.ncbi.nlm.nih.gov/37041650/

The faecal microbiota is distinct in HLA-B27+ ankylosing spondylitis patients versus HLA-B27+ healthy controls (2023)
https://pubmed.ncbi.nlm.nih.gov/36441657/

Why Do Some Patients Have Severe Sacroiliac Disease But No Syndesmophytes in Ankylosing Spondylitis? Data From a Nested Case-Control Study (2023)
https://pubmed.ncbi.nlm.nih.gov/36182115/

Environmental Risks for Spondyloarthropathies (2022)
https://pubmed.ncbi.nlm.nih.gov/36332997/

Correction: Stoll et al. Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients. Children 2022, 9, 569 (2022)
https://pubmed.ncbi.nlm.nih.gov/36010158/

Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension Study (2022)
https://pubmed.ncbi.nlm.nih.gov/35833532/

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study (2022)
https://pubmed.ncbi.nlm.nih.gov/35653615/

Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients (2022)
https://pubmed.ncbi.nlm.nih.gov/35455612/

Chronic inflammatory back pain commencing late in life: a neglected concept (2022)
https://pubmed.ncbi.nlm.nih.gov/35307928/

Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years (2022)
https://pubmed.ncbi.nlm.nih.gov/34853086/

The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort. (2021)
https://pubmed.ncbi.nlm.nih.gov/34853088/

Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years (2021)
https://pubmed.ncbi.nlm.nih.gov/34853086/

Biomarkers in axial spondyloarthritis and low back pain: a comprehensive review (2021)
https://pubmed.ncbi.nlm.nih.gov/34674081/

The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment (2021)
https://pubmed.ncbi.nlm.nih.gov/34599048/

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthriti (2021)
https://pubmed.ncbi.nlm.nih.gov/34534275/

Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis: A 15-year follow up study of the PSOAS Cohort (2021)
https://pubmed.ncbi.nlm.nih.gov/34427579/

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis (2021)
https://pubmed.ncbi.nlm.nih.gov/34161253/

HLA-B27 is associated with reduced disease activity in axial spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/34112886/

Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis (2021)
https://pubmed.ncbi.nlm.nih.gov/34042330/

Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry (2021)
https://pubmed.ncbi.nlm.nih.gov/33985940/

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y) (2021)
https://pubmed.ncbi.nlm.nih.gov/33958326/

Single-cell analysis reveals innate immunity dynamics in ankylosing spondylitis. (2021)
https://pubmed.ncbi.nlm.nih.gov/33784007/

Ankylosing spondylitis risk factors: a systematic literature review (2021)
https://pubmed.ncbi.nlm.nih.gov/33754220/

Validation of the Ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/33128725/

The Effect of HLA-B27 on Susceptibility and Severity of COVID-19 (2021)
https://pubmed.ncbi.nlm.nih.gov/33060311/

The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial (2021)
https://pubmed.ncbi.nlm.nih.gov/32926247/

Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study (2021)
https://pubmed.ncbi.nlm.nih.gov/32611668/

Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time (2020)
https://pubmed.ncbi.nlm.nih.gov/33243782/

Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial (2020)
https://pubmed.ncbi.nlm.nih.gov/33032770/

Correction to: The IgG galactosylation ratio is higher in spondyloarthritis patients and associated with the MRI score (2020)
https://pubmed.ncbi.nlm.nih.gov/32757077/

The changing profile of ankylosing spondylitis in the biologic era (2020)
https://pubmed.ncbi.nlm.nih.gov/32648102/

Content validity of the ASQoL for use in a non-radiographic axial spondyloarthritis population: a qualitative study (2020)
https://pubmed.ncbi.nlm.nih.gov/32607793/

Biologics, spondylitis and COVID-1 (2020)
https://pubmed.ncbi.nlm.nih.gov/32522741/

Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci (2020)
https://pubmed.ncbi.nlm.nih.gov/32492107/

Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort (2020)
https://pubmed.ncbi.nlm.nih.gov/32166439/

The IgG galactosylation ratio is higher in spondyloarthritis patients and associated with the MRI score (2020)
https://pubmed.ncbi.nlm.nih.gov/32124128/

A rare variant of RNF123 in familial ankylosing spondylitis causes dysfunction of osteoclast formation (2020)
https://pubmed.ncbi.nlm.nih.gov/31697389/

A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values (2020)
https://pubmed.ncbi.nlm.nih.gov/31730441/

Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis (2020)
https://pubmed.ncbi.nlm.nih.gov/31529687/

Reliability and Validity of Patient-reported Outcomes Measurement Information System Short Forms in Ankylosing Spondylitis (2020)
https://pubmed.ncbi.nlm.nih.gov/31371654/

Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis (2020)
https://pubmed.ncbi.nlm.nih.gov/30659049/

IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis (2019)
https://pubmed.ncbi.nlm.nih.gov/31195969/

Cauda Equina Syndrome in Ankylosing Spondylitis: Challenges in Diagnosis, Management, and Pathogenesis (2019)
https://pubmed.ncbi.nlm.nih.gov/30936280/

Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study (2019)
https://pubmed.ncbi.nlm.nih.gov/30824635/

Genetic association of non-MHC region with ankylosing spondylitis in a Chinese population (2019)
https://pubmed.ncbi.nlm.nih.gov/30552171/

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors (2019)
https://pubmed.ncbi.nlm.nih.gov/30343531/

HLA class I and II alleles in susceptibility to ankylosing spondylitis (2019)
https://pubmed.ncbi.nlm.nih.gov/30341055/

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled tria (2018)
https://pubmed.ncbi.nlm.nih.gov/30360964/

Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort (2018)
https://pubmed.ncbi.nlm.nih.gov/30094388/

Smoking quantity determines disease activity and function in Chinese patients with ankylosing spondylitis (2018)
https://pubmed.ncbi.nlm.nih.gov/29589132/

A multiple imputation method based on weighted quantile regression models for longitudinal censored biomarker data with missing values at early visits (2018)
https://pubmed.ncbi.nlm.nih.gov/29325529/

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study (2018)
https://pubmed.ncbi.nlm.nih.gov/29247154/

Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohor (2018)
https://pubmed.ncbi.nlm.nih.gov/29196383/

Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups (2017)
https://pubmed.ncbi.nlm.nih.gov/28780639/

Clinical patterns and characteristics of ankylosing spondylitis in China (2017)
https://pubmed.ncbi.nlm.nih.gov/28550390/

Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study (2017)
https://pubmed.ncbi.nlm.nih.gov/28432524/

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis (2017)
https://pubmed.ncbi.nlm.nih.gov/28087505/

A family-based genome-wide association study reveals an association of spondyloarthritis with MAPK14 (2017)
https://pubmed.ncbi.nlm.nih.gov/27461236/